Dillon & Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.76M | Buy |
25,195
+1,013
| +4% | +$70.9K | 0.24% | 45 |
|
|
2025
Q1 | $1.79M | Sell |
24,182
-6,090
| -20% | -$451K | 0.27% | 45 |
|
|
2024
Q4 | $2M | Sell |
30,272
-2,578
| -8% | -$170K | 0.28% | 45 |
|
|
2024
Q3 | $2.56M | Buy |
32,850
+7,013
| +27% | +$547K | 0.36% | 41 |
|
|
2024
Q2 | $2.02M | Buy |
25,837
+1,750
| +7% | +$136K | 0.29% | 46 |
|
|
2024
Q1 | $1.64M | Buy |
24,087
+846
| +4% | +$57.5K | 0.26% | 48 |
|
|
2023
Q4 | $1.56M | Buy |
23,241
+885
| +4% | +$59.3K | 0.28% | 49 |
|
|
2023
Q3 | $1.52M | Buy |
22,356
+1,475
| +7% | +$100K | 0.29% | 48 |
|
|
2023
Q2 | $1.5M | Buy |
20,881
+2,688
| +15% | +$193K | 0.28% | 51 |
|
|
2023
Q1 | $1.26M | Buy |
18,193
+1,846
| +11% | +$127K | 0.25% | 51 |
|
|
2022
Q4 | $1.11M | Buy |
16,347
+2,397
| +17% | +$163K | 0.24% | 52 |
|
|
2022
Q3 | $767K | Buy |
13,950
+3,303
| +31% | +$182K | 0.18% | 54 |
|
|
2022
Q2 | $703K | Buy |
10,647
+1,843
| +21% | +$122K | 0.16% | 53 |
|
|
2022
Q1 | $581K | Buy |
8,804
+2,139
| +32% | +$141K | 0.11% | 54 |
|
|
2021
Q4 | $387K | Buy |
+6,665
| New | +$387K | 0.07% | 59 |
|